363 related articles for article (PubMed ID: 26169267)
1. Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.
Cabrera-Mora M; Fonseca JA; Singh B; Oliveira-Ferreira J; Lima-Junior Jda C; Calvo-Calle JM; Moreno A
Infect Immun; 2015 Sep; 83(9):3749-61. PubMed ID: 26169267
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
[TBL] [Abstract][Full Text] [Related]
3. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
[TBL] [Abstract][Full Text] [Related]
4. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
[TBL] [Abstract][Full Text] [Related]
5. A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1
Fonseca JA; Cabrera-Mora M; Singh B; Oliveira-Ferreira J; da Costa Lima-Junior J; Calvo-Calle JM; Lozano JM; Moreno A
Sci Rep; 2016 Oct; 6():34527. PubMed ID: 27708348
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax.
Suphavilai C; Looareesuwan S; Good MF
Am J Trop Med Hyg; 2004 Jul; 71(1):29-39. PubMed ID: 15238685
[TBL] [Abstract][Full Text] [Related]
8. Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites.
Bilsborough J; Baumgart K; Bathurst I; Barr P; Good MF
Acta Trop; 1997 May; 65(2):59-80. PubMed ID: 9164601
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon.
Ferreira AR; Singh B; Cabrera-Mora M; Magri De Souza AC; Queiroz Marques MT; Porto LC; Santos F; Banic DM; Calvo-Calle JM; Oliveira-Ferreira J; Moreno A; Lima-Junior JC
PLoS One; 2014; 9(8):e105828. PubMed ID: 25148251
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
[TBL] [Abstract][Full Text] [Related]
12. Natural infections with different Plasmodium species induce antibodies reactive to a chimeric Plasmodium vivax recombinant protein.
McCaffery JN; Singh B; Nace D; Moreno A; Udhayakumar V; Rogier E
Malar J; 2021 Feb; 20(1):86. PubMed ID: 33579292
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.
Caro-Aguilar I; Rodríguez A; Calvo-Calle JM; Guzmán F; De la Vega P; Patarroyo ME; Galinski MR; Moreno A
Infect Immun; 2002 Jul; 70(7):3479-92. PubMed ID: 12065487
[TBL] [Abstract][Full Text] [Related]
15. Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys.
Arévalo-Herrera M; Roggero MA; Gonzalez JM; Vergara J; Corradin G; López JA; Herrera S
Ann Trop Med Parasitol; 1998 Jul; 92(5):539-51. PubMed ID: 9797827
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of synthetic peptide constructs based on PvMSP9
Rodrigues-da-Silva RN; Correa-Moreira D; Soares IF; de-Luca PM; Totino PRR; Morgado FN; Oliveira Henriques MDG; Peixoto Candea AL; Singh B; Galinski MR; Moreno A; Oliveira-Ferreira J; Lima-Junior JDC
Vaccine; 2019 Jan; 37(2):306-313. PubMed ID: 30509693
[TBL] [Abstract][Full Text] [Related]
19. Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients.
Nateghpour M; Etemadi S; Motevalli Haghi A; Eslami H; Mohebali M; Farivar L
Eur J Med Res; 2021 Nov; 26(1):134. PubMed ID: 34823591
[TBL] [Abstract][Full Text] [Related]
20. Importance of the Immunodominant CD8
Gibbins MP; Müller K; Glover M; Liu J; Putrianti ED; Bauza K; Reyes-Sandoval A; Matuschewski K; Silvie O; Hafalla JCR
Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32719159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
